Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Cowen Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 6:56 AM EDTCowen initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $14.70 yesterday.
... More


